Key facts
- Watercress Research’s last known valuation is $4.4M (Aug 2025).
- It has raised $1.5M; the latest was Later Stage VC ($550K) in Aug 2025.
- Notable investors include Exeter Innovation, KCP Nominees, QantX, University of Exeter, West Midlands Health Tech Innovation Accelerator.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Watercress Research
- ·The full record, as it builds
Funding rounds
No funding rounds for Watercress Research are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Watercress Research
Operator of a phytochemical therapeutics platform intended to generate urease-inhibiting products from watercress. The company offers research into natural extracts, including PEITC, protein extracts for urease inhibition, the development of own-brand products, contract collaborations, and applications in continence care, cosmetics, food & drink, enabling companies to access scientifically validated plant-based bioactive compounds for health, skincare, and nutritional uses.
- Sector
- Healthcare
- HQ
- Exeter, United Kingdom
- Founded
- 2019
- Employees
- 5
- Website
- watercressresearch.com/
- Ownership
- Privately Held (backing)
Watercress Research doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Watercress Research shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Watercress Research in its N-PORT filings yet. We sweep new filings monthly.